-
Share
222 Posts.
9
11/04/18
22:44
Share
Hi Lopez
The Keynote 200 trial looks like it is tracking well and the upregulation of PD-L1 in NSCLC and bladder cancer looks promising.
I'm still disappointed at the pace of the MITCI & CAPRA trials .... still recruiting very slowly but the results are looking excellent.
I think today's announcement will help to clarify the results from the presentation.
GLTAH
-